Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Amortization - Intangibles (2016 - 2026)

Aytu Biopharma has reported Amortization - Intangibles over the past 11 years, most recently at $526000.0 for Q4 2025.

  • Quarterly Amortization - Intangibles fell 42.89% to $526000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 23.68% year-over-year, with the annual reading at $3.7 million for FY2025, 0.0% changed from the prior year.
  • Amortization - Intangibles was $526000.0 for Q4 2025 at Aytu Biopharma, up from $444000.0 in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $1.5 million in Q3 2021 and troughed at $444000.0 in Q3 2025.
  • The 5-year median for Amortization - Intangibles is $924000.0 (2023), against an average of $1.1 million.
  • Year-over-year, Amortization - Intangibles grew 3.43% in 2022 and then crashed 51.79% in 2025.
  • A 5-year view of Amortization - Intangibles shows it stood at $1.5 million in 2021, then fell by 20.4% to $1.2 million in 2022, then decreased by 23.37% to $918000.0 in 2023, then rose by 0.33% to $921000.0 in 2024, then crashed by 42.89% to $526000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Amortization - Intangibles are $526000.0 (Q4 2025), $444000.0 (Q3 2025), and $921000.0 (Q2 2025).